

# Utilization of Blood Cultures, Risk factors and Outcomes of Bloodstream Infections in Patients Hospitalized with COVID-19

Smitha Gudipati, Amit Vahia, Nicole Pahl, Indira Brar, Geehan Suleyman, Samia Arshad, Marcus Zervos, George Alangaden Henry Ford Health System, Detroit, MI


# Introduction

- During the coronavirus disease 2019 (COVID-19) surge, there was a sharp increase of blood cultures (BC) performed at Henry Ford Health System (HFHS).
- However, the epidemiology and outcomes of bloodstream infections (BSI) in COVID-19 patients (pts) remains undefined.
- We report the utilization of blood cultures, risk factors and mortality associated with BSI in a large cohort of COVID-19 pts.

## Methods

- A retrospective analysis was performed of all COVID-19 pts that had BC performed during hospitalization at HFHS, a 5-hospital system in southeast Michigan.
- Study period 3-10-20 to 4-28-20.
- BSI was defined using NHSN criteria.
- Demographics, comorbidities, severity of illness and outcome of pts with and without BSI were compared.
- Comparisons were performed using Chi square testing for categorical variables and Student's T test for continuous variables.

### Results



Results				<b>Results</b> Risk Factors Associated with Mortality - Multivariate Analysis				
Table 1. Characteristics of COVID-19 Patients with BSI Compared to COVID-19 Patients without BSI								
				Variable	Odds Ratio (95% CI)		<b>P</b> value	
Variable	COVID-19 pts with	<b>COVID-19</b> pts without	<b>P</b> value	Age	1.07 (1.06-1.08)		<0.0001	
	BSI	BSI		ICU stay	7.91 (5.75-10.87)	•	<0.0001	
	(N=80)	(N=1313)		mSOFA score	1.29 (1.13-1.47)		<0.0001	
Age – Mean (SD)	70.1 (13.8)	64.5 (15.9)	0.0024	BSI	1.69 [CI: 0.99-2.89],		< 0.056	
Male gender - N (%)	36 (45.0)	717 (54.6)	0.0941	Figure 1 (	Cumulative Number of I	Bloodstream Pa	thogens	
Race/ethnicity - N (%)			0.3556	riguie 1. C			unogens	
Black	51 (63.8)	726 (55.3)		S. aureus				
White	25 (31.3)	457 (34.8)		Streptococcus sp.				
Body mass index (N=271)	(N=78)	(N=1258)	0.0935					
Continuous – Mean (SD)	31 (9.8)	31.8 (8.4)		Enterococcus sp.				
Max mSOFA score (N=232)	(N=64)	(N=954)	<0.0001	E. coli				
Med.(IQR)	6.5 (3-8.5)	4 (2-6)		P. aeruginosa				
Length of stay – Med. (IQR)	12 (5.5-20)	8 (5-13)	0.0013	Unspecified				
ICU admission – Med. (IQR)	47 (58.8)	453 (34.5)	<0.0001	P. mirabilis				
Mechanical ventilation – Med.(IQR)	43 (53.75)	351 (26.73)	<0.0001	Candida sp.				
<b>D</b> escript of storoids $N(0/)$	50 (62.5)	932 (71)	0.1063	K. pneumoniae				
Receipt of steroids N (%)	50 (02.5)	932 (71)		P.acnes				
O2 saturation at presentation		210(10)	0.2523	S. marcescens				
≥95 90-94	18 (22.5)	210(16)		A. baumanii				
86-89	32 (40) 14 (17.5)	664 (50.6) 216 (16.5)						
$\leq 85$	14(17.5) 16(20)	210(10.5) 223(17)		S. lugdunensis				
				Prevotella denticola				
<b>Co-morbidities</b> – Mean (SD)	1 (1 0 5)		1 0000	Lactobacillus sp.				
Immunodeficiency	1(1.25)	24(1.8)	1.0000	Citrobacter koseri				
Pulmonary disease	56(70)	875 (66.7)	0.5356 0.9770	Aerococcus urinae		No. of patient isolat	es	
Cardiac disease Chronic kidney disease	8 (10) 56 (70)	130 (9.9) 619 (47.1)	<pre>0.9770 &lt;0.0001</pre>		E	10	15	
Chronic obstructive lung disease	15 (18.8)	198 (15.1)	0.3759		J J	10	15	20
Hypertension	60 (75)	888 (67.6)	0.1700	Conclusion				
Asthma	9 (11.3)	120 (9.4)	0.5272					
Cancer	20 (25)	222 (16.9)	0.0636	• Although more	than half of hospitalized	COVID_10 nto	had RC do	ne the
Diabetes mellitus	44 (55)	513 (39.1)	0.0047	e	*	<b>A</b>		110, tHO
Central line (N=52)	18 (22.5)	147 (11.2)	0.0024	<ul> <li>number of BSI were low suggesting overutilization of BC.</li> <li>BSI was associated with older age and disease severity.</li> </ul>				
Mortality	39 (48.8)	325 (24.8)	<0.0001	• Mortality was not affected by BSI but was primarily driven by age and				
				severity of illne	•	<b>⊥</b> ✓		



